Literature DB >> 25612178

Highlights of the 2014 International AIDS Conference: update from down under.

Paul A Volberding1.   

Abstract

The 20th International AIDS Conference held in Melbourne, Australia, from July 20 through July 25, 2014, provided much new data on nucleoside analogue reverse transcriptase inhibitor-sparing antiretroviral therapy, potential consequences of switching suppressive antiretroviral regimen, antiretroviral treatment with integrase strand transfer inhibitors, effects of antiretroviral therapy on HIV-associated neurocognitive impairment, and hepatitis C virus (HCV) treatment in HIV/HCV-coinfected individuals. This article summarizes an IAS-USA continuing education webinar presented by Paul A. Volberding, MD, in August 2014, in which he focused on a few select highlights from the Conference.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25612178      PMCID: PMC6148894     

Source DB:  PubMed          Journal:  Top Antivir Med        ISSN: 2161-5853


  1 in total

1.  Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial.

Authors:  Pedro Cahn; Jaime Andrade-Villanueva; José R Arribas; José M Gatell; Javier R Lama; Michael Norton; Patricia Patterson; Juan Sierra Madero; Omar Sued; Maria Inés Figueroa; Maria José Rolon
Journal:  Lancet Infect Dis       Date:  2014-04-27       Impact factor: 25.071

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.